Abstract
Abdominal aortic aneurysms (AAA) are an important source of morbidity and mortality in the U.S. and worldwide. Treatment options are limited, with open surgery or endovascular repair remaining the only curative treatments. Classical cardiovascular medications have generally failed to prevent or significantly alter AAA formation or progression. Therefore, there is a tremendous need for better therapeutic approaches. With increasing knowledge of microRNA (miR) regulation in the context of cardiovascular disease, and with improving technical options permitting alteration of miRexpression levels in vitro and in vivo, we are offered a glimpse into the diagnostic and therapeutic possibilities of using miRs to treat vascular pathobiology.
This review focuses on the role of miRs in aneurysmal disease of the abdominal aorta, summarizing recent publications regarding this topic, and outlining known effects of relevant miRs in AAA formation, including miR-21 and miR-29b. Despite there being only limited studies available, several other miRs also display clear potential for alteration of the disease process including miR-26a, the miR-17-92-cluster, miRs-221/222, miR-133 and miR-146a. While studies have shown that miRs can regulate the activity and interplay of vascular inflammatory cells, endothelial cells, smooth muscle cells and fibroblasts, all key elements leading to AAA formation, much work remains to be done.
Keywords: Abdominal aortic aneurysms, endovascular repair, cardiovascular medications, therapeutic approaches, microRNA, vascular pathobiology.
Current Vascular Pharmacology
Title:MicroRNAs in Abdominal Aortic Aneurysm
Volume: 13 Issue: 3
Author(s): Matti Adam, Uwe Raaz, Joshua M. Spin and Philip S. Tsao
Affiliation:
Keywords: Abdominal aortic aneurysms, endovascular repair, cardiovascular medications, therapeutic approaches, microRNA, vascular pathobiology.
Abstract: Abdominal aortic aneurysms (AAA) are an important source of morbidity and mortality in the U.S. and worldwide. Treatment options are limited, with open surgery or endovascular repair remaining the only curative treatments. Classical cardiovascular medications have generally failed to prevent or significantly alter AAA formation or progression. Therefore, there is a tremendous need for better therapeutic approaches. With increasing knowledge of microRNA (miR) regulation in the context of cardiovascular disease, and with improving technical options permitting alteration of miRexpression levels in vitro and in vivo, we are offered a glimpse into the diagnostic and therapeutic possibilities of using miRs to treat vascular pathobiology.
This review focuses on the role of miRs in aneurysmal disease of the abdominal aorta, summarizing recent publications regarding this topic, and outlining known effects of relevant miRs in AAA formation, including miR-21 and miR-29b. Despite there being only limited studies available, several other miRs also display clear potential for alteration of the disease process including miR-26a, the miR-17-92-cluster, miRs-221/222, miR-133 and miR-146a. While studies have shown that miRs can regulate the activity and interplay of vascular inflammatory cells, endothelial cells, smooth muscle cells and fibroblasts, all key elements leading to AAA formation, much work remains to be done.
Export Options
About this article
Cite this article as:
Adam Matti, Raaz Uwe, Spin M. Joshua and Tsao S. Philip, MicroRNAs in Abdominal Aortic Aneurysm, Current Vascular Pharmacology 2015; 13 (3) . https://dx.doi.org/10.2174/15701611113119990015
DOI https://dx.doi.org/10.2174/15701611113119990015 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Intracranial MR Dynamics in Clinically Diagnosed Alzheimers Disease: The Emerging Concept of “Pulse Wave Encephalopathy”
Current Alzheimer Research The Cardiologist in the Periphery: Indications and Usefulness of Peripheral Artery Invasive Angiography in Patients Undergoing Coronary Angiography
Current Medical Imaging Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Novel Insights into Complex Cardiovascular Pathologies using 4D Flow Analysis by Cardiovascular Magnetic Resonance Imaging
Current Pharmaceutical Design Optimal Time for Pharmacological Treatment of Abdominal Aortic Aneurysm
Current Drug Targets The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery Contributory Role of Matrix Metalloproteinases in Cardiovascular Remodeling
Current Drug Targets - Cardiovascular & Hematological Disorders HDL Stimulates apoM Secretion
Protein & Peptide Letters miR-29c-3p is an Effective Biomarker of Abdominal Aortic Aneurysm in Patients Undergoing Elective Surgery
MicroRNA Proinflammatory Gene Polymorphisms and Ischemic Stroke
Current Pharmaceutical Design Beta-Blockers and Abdominal Aortic Aneurysm Growth: A Systematic Review and Meta-Analysis
Current Cardiology Reviews Impact of Mast Cell Chymase on Renal Disease Progression
Current Hypertension Reviews Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology Renovascular Hypertension: Lesion Detection, Patient Selection, Treatment Options and Results
Current Hypertension Reviews Impact of Tobacco Smoking on Lipid Metabolism, Body Weight and Cardiometabolic Risk
Current Pharmaceutical Design The Effects of Olprinone, a Phosphodiesterase 3 Inhibitor, on Systemic and Cerebral Circulation
Current Vascular Pharmacology Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research The Tree of Sirtuins and the Garden of Cardiovascular Youth
Current Vascular Pharmacology In vivo Optical Molecular Imaging of Cardiovascular Diseases: Long Road Ahead
Current Molecular Imaging (Discontinued)